ARCHIMEDlife is a highly-innovative diagnostic laboratory pioneering new ways to provide better and faster diagnostic services.
“From Inborn Errors of Metabolism to Oncology”
Personalized Medicine starts with Personalized Diagnostics for your optimal treatment and best clinical outcome.
From routine testing to clinical studies we are a laboratory service provider with strong focus on personalized diagnostics including rare disorders. Our promise is to provide high quality laboratory tests to identify any harmful disease at the earliest time for the best clinical outcome.
“Our commitment: improving health through better, faster and earlier diagnosis giving the best chance for treatment and best clinical outcomes.”
Diagnostics ・Research・Development
on 02 Sep, 2020
α-Mannosidosis is an inherited lysosomal storage disorder caused by genetic mutations leading to limited or no expression of a gene responsible for metabolizing oligosaccharides. Although α-Mannosidosis is considered to be ultra-rare, studies...
Read Moreon 18 Aug, 2020
Fabry disease (FD) is a X-linked inherited disorder where deficiency of the α-Galactosidase A (α-Gal A) enzyme causes Globotriaosylceramide (GL-3/Gb3) lipid accumulation in the cells of different organs. Due to random X-chromosome...
Read Moreon 04 Aug, 2020
Acid Sphingomyelinase deficiency (ASMD), also known as Niemann-Pick Type A/B, is characterized by an enzyme deficiency that leads to the toxic accumulation of sphingomyelin. “Recent studies show for every 3 – 5...
Read Moreon 15 Mar, 2020
We stay open for you and your patients! We used the last days to prepare us to continue our work and services on the highest safety and responsibility. Please communicate this to...
Read Moreon 18 Feb, 2020
Early diagnosis of hemoglobin disorders and Thalassemias are become more important due to a high carrier frequency and ease of global migration. In a prospective study of over 5,000 samples, we investigated...
Read More
on 17 Jan, 2020
ARCHIMEDlife is very proud to announce the strategic alliance with amedes Holding GmbH, a leading provider in interdisciplinary and medical-diagnostic services for patients, physicians and hospitals. Together, we will expand and continue...
Read More
on 25 Sep, 2019
Combining high-quality biochemical testing with innovative genetic testing forms a powerful tool for personalized medicine, clinical research and diagnostics in rare diseases. ARCHIMEDlife Medical Laboratory, based in Vienna, provides biochemical and genetic...
Read More
on 27 Aug, 2019
Exciting! Our booth with a brand new look and novel, innovative portfolio of diagnostic tests and services. First time presenting at SSIEM, 3 – 6 September, 2019 in Rotterdam, NL. Meet you...
Read More
on 06 Jun, 2019
We are happy to inform you that we have introduced a new diagnostic assay for the analysis of lysosomal enzyme activities from Dried Blood Spots using Clinical Mass Spectrometry. This new assay...
Read More
on 26 Feb, 2019
Quantitative Bestimmung von Psychopharmaka in Blut, Serum oder Plasma Modernste Analysetechnik mittels Klinischer Massenspektrometrie (exakt, sensitiv, schnell) Kompetente fachärztliche Auskunft Tägliche Bestimmungen: Montag – Freitag Download Zuweiserformular *NEU“: Vortioxetin Bestimmung Link: TDM
Read More
on 01 Oct, 2018
Results of a prospective study using High-Resolution Mass Spectrometry. The goal of our study, in cooperation with the University Medical Center Hamburg in Eppendorf Germany, was to evaluate both the efficacy of...
Read Moreon 14 Mar, 2018
LEA2 MPS Panel Our first LEA2 (Lysosomal Enzyme Activity) assay has now been started and with it several mucopolysaccharidoses (MPS) can be diagnosed from one single Dried Blood Spot within a few...
Read More
on 14 Mar, 2018
Our awarded work (Poster Finalist at MSACL Europe, also see the PDF Poster Hemoglobinopathies_MSACL) on hemoglobinopathies and thalassemias is now starting into a prospective study in cooperation with the University Medical Center Hamburg-Eppendorf,...
Read More
on 07 Mar, 2018
Introduction: Methods: Results: Conclusion: Authors / corresponding author* JAlbinaNowakaSarah H.HailebDavid C.KaspercThomas P.MechtlercAndreas J.FlammeraPierre A.KrayenbuehldDaniel P.Franzena University Hospital Zurich, Zurich, Switzerland b University Zurich, Zurich, Switzerland c ARCHIMED Life Science, Vienna, Austria...
Read More
on 07 Mar, 2018
The parallel measurement of lyso-GL-3 (lyso-Gb3) for Fabry disease is of high importance particularly for potential female Fabry patients, otherwise women at risk might be missed and consequently be undiagnosed. We analyzed...
Read More
on 21 Nov, 2017
The 21st of November 2017 is ARCHIMEDlife´s 5th anniversary, a proof that out of an idea you can evolve a successful company with dedicated people and ongoing improvement. It is time to...
Read More
on 13 Nov, 2017
Introduction: Diagnosis of neonatal sepsis remains a major challenge in neonatology. Most molecularbased methods are not customized for neonatal requirements. The aim of the present study was to assess the diagnostic accuracy...
Read More
on 12 Nov, 2017
You can easily subscribe to our bi-monthly ARCHIMEDlife Newsletter and read about laboratory diagnostics, research studies, scientific publications and rare diseases – first hand and for free! If you do not want...
Read More
on 06 Nov, 2017
We took part in the 12th Asia-Pacific Conference on Human Genetics “Genomic Medicine and Clinical Practice” from 8th to 10th of November in Bangkok. Medical scientists, genetic experts and healthcare professionals from...
Read More
on 16 Oct, 2017
Pharmaboardroom.com interviewed ARCHIMEDlife CEO David Kasper for their latest Austria issue of “Healthcare and Life Sciences Review”. Find out why he founded ARCHIMEDlife in a privately-held setting and which needs ARCHIMEDlife satisfies...
Read More
